Selank Research Overview
Selank is a tuftsin-derived synthetic peptide investigated in gene-expression responses involving neurotransmission and immune-related pathways. Its research should not be reduced to the assertion that it “is a GABA agonist”. Rat-brain, cultured neuroblastoma and mouse-spleen experiments have used different models, co-exposures and endpoints, sometimes with materially different findings.
Research Use Only: This article interprets laboratory and preclinical literature. It does not support treatment for anxiety, cognitive enhancement, human or veterinary administration, or any personal-use protocol.
How does Selank relate to tuftsin?
Selank is commonly described as a modified tuftsin-derived peptide with a Pro-Gly-Pro-related extension. Its structural relationship to tuftsin provides one background rationale for research, not proof that every tuftsin finding also occurs with Selank. Likewise, a Gly-Pro fragment cannot be treated automatically as the same molecule as intact Selank.
In a publication, the exact material matters: full Selank, a named fragment, an experimental mixture and the supplied commercial material are different identification claims. The label alone does not establish terminal modifications, salt/counter-ion composition or any batch’s mass-spectrum result.
What did the rat-brain transcript studies observe?
Volkova and colleagues (2016) compared gene-expression responses after experimental exposure to Selank or GABA in rat frontal cortex. The authors assessed a panel of genes involved in neurotransmission and reported changes at the timepoints studied, with correlations between parts of the Selank- and GABA-associated expression patterns.
These findings concern mRNA abundance in a specified rat-brain preparation. A transcript changing does not establish direct binding at GABAA receptors, and it does not establish the same effect in another brain region, isolated neuronal culture or person. The study described potential modulation, not a definitive universal receptor agonist mechanism.
A contrasting result from IMR-32 cultured cells
A later IMR-32 neuroblastoma-cell study examined a neurotransmission-related gene panel after exposure to Selank, GABA, olanzapine or combinations. Selank alone did not significantly change the measured mRNA levels in that experimental setting. By contrast, co-exposures with GABA or olanzapine changed some patterns relative to the respective comparators.
This result is central, not inconvenient. It shows why “Selank always changes GABAergic gene expression” fails as a research summary. A response to Selank plus another substance cannot be assigned to Selank alone, and a response in rat brain tissue is not guaranteed in a human neuroblastoma-derived cell line.
| Study component | Model | Reported feature | Necessary interpretation limit |
|---|---|---|---|
| Volkova et al., 2016 | Rat frontal cortex | Selank/GABA-associated changes in measured neurotransmission transcripts | Not direct receptor binding or a human behavioural result |
| IMR-32 study, 2017 | Cultured neuroblastoma cells | No change with Selank alone in the reported gene panel; altered patterns with co-exposure | Does not prove a uniform effect in other cell systems |
| Kolomin et al., 2014 | Mouse spleen | Time-dependent immune-gene mRNA changes after Selank/fragment exposure | Not a general immune benefit or human clinical finding |
These results are grouped for method comparison, not pooled statistically and not a claim that the materials underwent a common experimental protocol.
Why mouse-spleen results add a different research question
Kolomin and colleagues studied time-dependent expression of inflammation-related genes in mouse spleen following Selank or a short fragment. Their targets included transcripts such as C3, Casp1, Il2rg and Xcr1. The report described different temporal profiles and overlap between intact peptide and fragment conditions for some genes.
The study concerns immune-gene transcription in an animal organ, not a validated effect on the human immune system. It also illustrates that a molecule’s fragment may share some responses while remaining chemically distinct from the parent. This is the appropriate level of interpretation for that paper.
How should a Selank experiment be described in a research review?
Ask six questions before citing the result:
- Material identity: Was intact Selank tested, a known fragment, tuftsin, or a formulated mixture?
- Biological system: Brain tissue, cultured cells, spleen, other animal system or human observation?
- Co-exposure: Was Selank alone or combined with a second agent?
- Endpoint: mRNA, protein, receptor binding, electrophysiology, inflammatory response or behaviour?
- Timepoint: Did the experiment measure an immediate response, a later transcript change or a sustained effect?
- Negative findings: Were any measured targets unchanged, and were appropriate controls present?
An isolated positive gene name without these details risks implying more than the paper measured. A meaningful synthesis keeps the null result from IMR-32 next to the rat-brain findings and distinguishes direct pharmacology from downstream transcription.
Selank versus Semax
Selank and Semax are different synthetic-peptide families, despite both being described with PGP-related structural features. Semax research includes ACTH-fragment-related neurotrophin and experimental injury-model work. Selank research discussed here concerns tuftsin-derived material and different transcript-level questions. Shared words such as “neuropeptide” or “PGP” do not establish interchangeable receptor mechanisms or chemical identity.
The neuroregulatory comparison matrix puts those different evidence layers in one place alongside DSIP and Kisspeptin-10, without claiming the compounds have equivalent effects.
What can a Core Research Selank batch report establish?
The supplied material requires its own actual sequence/form declaration, analytical identity, lot match and suitable measurements. Generic literature does not authenticate a commercial vial; a statement about mRNA changes is not a purity assay. Distinguish a chromatographic result from molecular identity, total content or finished-format properties.
Use Batch Documentation and the CoA-reading guide. Core Research lists a Selank 10mg vial and Selank Refill 10mg, which are separate presentations. Cartridge compatibility and fill data require their own product-specific documentation, not a gene-expression paper.
Selected research references
- Volkova A et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology, 2016. DOI: 10.3389/fphar.2016.00031.
- GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. 2017. PMID: 28293190. Includes the important no-effect-alone observation.
- Kolomin T et al. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Molecular Immunology, 2014. DOI: 10.1016/j.molimm.2013.11.002.